胃肠道外MALT淋巴瘤

目的:探讨胃肠道外MALT淋巴瘤临床病理特点.方法:复习14例胃肠道外MALT淋巴瘤临床病理资料及病理切片.结果:胃肠道外MALT淋巴瘤占MALT淋巴瘤的42.42%,发病中位年龄为50岁,85.71%为Ann Arbor Ⅰ期,42.86%发生于眼部.肿瘤细胞以边缘区B细胞样细胞为主,伴有少量免疫母细胞样细胞及浆细胞,1例可见大细胞转化区.随访11例,10例存活,1例死亡.结论:胃肠道外MALT淋巴瘤患者发病年龄较胃肠道患者年龄小,好发于眼部,较少向大细胞淋巴瘤转化.     

25例眼附属器原发恶性淋巴瘤的特点及疗效

目的研究眼附属器原发恶性淋巴瘤的病理及临床特点,分析疗效,探讨减少放疗并发症的方法。方法眼附属器原发恶性淋巴瘤25例中,男11例,女14例。所有病例均经病理证实,其中19例行活检术,6例行肿瘤切除术。单眼发病22例,双眼同时受侵3例。肿瘤原发于眼睑或结膜16例（19眼）,原发于眶内其他部位9例。Ann Arbor分期ⅠE期2l例,ⅡE期3例,ⅢE期1例。22例（25眼）接受了放疗,采用180 kV深部X线或^（60）Coγ线或混合线照射,放疗剂量为30．0～57．6 Gy。结果全组5、10年生存率分别为90%、82%;原发于眼睑或结膜、原发于眶内的10年生存率分别为100%、58%（P=0．032）。肿瘤全切和肿瘤残留的10生存率分别为83%和82%（P=0．907）,局部控制率分别为80%和95%（P=0．369）。放疗组局部控制率为92%,未接受放疗组局部控制率为33%（P=0．006）。全组中22例为黏膜相关淋巴组织（MALT）淋巴瘤,2例大B细胞淋巴瘤,1例为T细胞淋巴瘤。MALT淋巴瘤和非MALT淋巴瘤的10年生存率分别为90%和33%（P=0．009）。全组中8眼发生放射诱发的白内障,7眼出现眼干燥症。结论眼附属器淋巴瘤放疗可以取得良好的效果,原发于眼睑、结膜者预后好于原发于眶内者。眼附属器淋巴瘤以MALT为主,其预后明显好于非MALT淋巴瘤者。放疗并发症主要为白内障和干眼症,通过合理设计放疗计划,给予适当的放疗剂量可有效降低并发症。     

胃肠道外MALT淋巴瘤

目的：探讨胃肠道外MALT淋巴瘤临床病理特点。方法：复习14例胃肠道外MALT淋巴瘤临床病理资料及病理切片。结果：胃肠道外MALT淋巴瘤占MALT淋巴瘤的42．42％，发病中位年龄为50岁，85．71％为Ann Arhot Ⅰ期，42．86％发生于眼部。肿瘤细胞以边缘区B细胞样细胞为主，伴有少量免疫母细胞样细胞及浆细胞，1例可见大细胞转化区。随访11例，10例存活，1例死亡。结论：胃肠道外MALT淋巴瘤患者发病年龄较胃肠道患者年龄小，好发于眼部，较少向大细胞淋巴瘤转化。     

40例早期胃外黏膜相关淋巴组织淋巴瘤的治疗结果

目的 分析胃外黏膜相关淋巴组织(MALT)淋巴瘤的临床特征和预后.方法 回顾性分析40例首程治疗的Ⅰ_E～Ⅱ_E期原发胃外MALT淋巴瘤,其中男女比例为1:2,中位年龄54岁.原发病部位为肠道10例,眼附属器9例,甲状腺8例,肺5例,韦氏环2例及其他部位6例.Ⅰ_E期27例,Ⅱ_E期13.17例患者接受放疗(其中7例合并化疗),18例接受化疗(未合并放疗),5例单纯手术切除.结果 中位随访58个月.5年总生存率和无进展生存率分别为86%和82%.Ⅰ_E期和Ⅱ_E期5年总生存率分别为92%和76%(χ~23.66,P=0.060),无进展生存率分别为85%和76%(χ~2=1.04,P=0.300).原发眼附属器MALT淋巴瘤的5年总生存率和无进展生存率均为100%.17例接受放疗的患者无局部区域复发,局部区域控制率为100%,而23例未接受放疗者局部区域复发率为13%(3例).结论 Ⅰ_E期胃外MALT淋巴瘤可取得较好的治疗效果,放疗仍是标准治疗手段,原发眼附属器MALT淋巴瘤预后最好.     

180例黏膜相关淋巴瘤患者的临床特征和预后分析

  目的   对黏膜相关淋巴组织（mucosa associated lymphoid tissue，MALT）进行较大样本的单中心回顾性分析，获取其临床特征及生存相关影响因素数据。   方法   回顾性分析2012年9月至2019年5月陆军军医大学大坪医院经病理活检确诊的180例MALT淋巴瘤患者。   结果   全组180例患者，其中男性99例（55.0%），女性81例（45.0%），发病年龄31~84岁，中位年龄57岁。原发部位为胃肠59例（32.8%），眼66例（36.7%），其他结外原发部位包括肺、咽淋巴环、甲状腺、腮腺和睾丸等，共55例（30.6%）。临床分期Ⅰ~Ⅱ期173例（96.1%），Ⅲ~Ⅳ期7例（3.9%）。胃肠组、眼部组和其他组5年生存率（overall survival，OS）分别为96.7%、95.5%和86.4%，差异无统计学意义（P=0.118）；5年无进展生存率（progression-free survival，PFS）分别为82.4%、86.6%和86.4%，差异无统计学意义（P=0.862）。预后单因素相关分析提示，低血红蛋白水平（P=0.006）、β2-微球蛋白（β2-MG）升高（P=0.013）为影响患者OS的相关因素；β2-MG升高（P=0.004）为影响患者OS及PFS的相关因素。多因素分析表明低血红蛋白水平与生存期有关（P=0.015）。   Conclusions:   MALT淋巴瘤可起源于全身不同部位，其临床过程进展缓慢，复发晚，OS较长。低血红蛋白水平、β2-MG可作为MALT淋巴瘤重要的临床预后指标。      

原发性胃肠道淋巴瘤的诊断与治疗

目的探讨原发性胃肠道淋巴瘤的临床特点及诊治方法。方法1983年至2004年在北京大学第一医院外科接受治疗的原发性胃肠道淋巴瘤患者35例,对其临床病理资料及预后进行回顾性分析。结果本组原发性胃肠道淋巴瘤术前诊断率仅为20.0%;18例胃淋巴瘤中16例接受手术治疗,其中12例行根治性切除;17例肠道淋巴瘤均手术治疗,其中14例行根治性切除;Ann Ar-bor临床分期为:ⅠE期14例,ⅡE期10例,ⅢE期1例,ⅣE期10例。MALT淋巴瘤与非MALT淋巴瘤在年龄、性别及发病部位及早晚分期上差异无显著性。MALT淋巴瘤组手术根治率(92.9%)高于非MALT淋巴瘤(68.4%),MALT淋巴瘤组淋巴结转移率(42.9%)明显低于非MALT淋巴瘤组(84.2%)。结论胃肠道淋巴瘤临床表现缺乏特异性,术前诊断率低;胃淋巴瘤与肠淋巴瘤在性别、年龄、手术根治性及临床分期方面无明显区别;MALT淋巴瘤组确诊时分期较早,手术根治率高,淋巴结转移率低,预后优于非MALT淋巴瘤组。外科手术是诊断和治疗原发性胃肠道淋巴瘤的主要方法。     

原发性胃肠道非霍奇金淋巴瘤的临床研究

目的：回顾性分析原发性胃肠道非霍奇金淋巴瘤（PGI NHL）的形态学和病理类型、临床特征、治疗及预后。方法：收集病理确诊的原发性胃肠道非霍奇金淋巴瘤89例，行常规病理和免疫组化染色（CD3、CD5、CD7、CD10、CD20、CD23、CD45RO、Kappa、Lambda、Cyclin D1、Ki-67），按照WHO分类方法重新分类，借以探讨其临床特征。结果：①ⅠE期24例，ⅡE期33例，ⅢE期19例，ⅣE期13例。②T细胞性和B细胞性PGI NHL各17例和72例。③MALT淋巴瘤共15例，其中胃MALT瘤14例，小肠1例。④3、5年总生存率直接法计算分别为77.0%（57/74）和53.6（30/56）。其中ⅠE期24例，3、5年总生存率分别为100%（19/19）和85.7%（12/14），ⅡE期33例，3、5总生存率分别为85.2%（23/27）和65%（13/20），ⅢE期19例，3、5年总生存率分别为58.8%（10/17）和30.8%(4/13),ⅣE期13例，3、5年总生存率分别为45.5%（5/11）和11.1%(1/9)。结论：PGI NHL临床表现无特异性，容易延误诊断；胃癌发生率最高，临床分期以ⅠE、ⅡE期为主，病理分型以中度恶性和B细胞性为主，ⅠE期和ⅡE期临床预后明显比ⅢE期好，B细胞性临床预后较T细胞性好；根治性手术和术后正规化疗，必要时加用放疗是取得长期生存的重要措施。     

BIOMED-2体系检测免疫球蛋白重链基因重排在黏膜相关淋巴组织结外边缘区B细胞淋巴瘤诊断中的应用

 【摘要】　目的　探讨BIOMED-2标准化体系检测免疫球蛋白重链（IGH）基因重排对黏膜相关淋巴组织结外边缘区B细胞淋巴瘤（MALT淋巴瘤）诊断的应用价值。方法　45例标本包括不同部位原发的MALT淋巴瘤36例、淋巴结外淋巴组织增生性病变3例、幽门螺杆菌（HP）感染相关性重度胃炎6例。用DNA提取试剂盒从石蜡包埋组织中提取所选病例的基因组DNA,通过BIOMED-2体系质控混合引物检测其质量,应用IGH VH-JH 3组引物组合进行IGH基因克隆性重排检测;比较分析该体系在MALT淋巴瘤诊断中的敏感性和特异性。结果　45例中31例（MALT淋巴瘤22例,淋巴组织增生性病变3例、重度胃炎6例）提取的基因组DNA可扩增出300 bp片段,其余14例DNA均严重降解。22例MALT淋巴瘤中,16例检测出IGH基因重排,灵敏度为72.7 %;6例严重胃炎病例未检测出IGH克隆性重排,其特异度是100 %;3例淋巴组织增生性病变中1例检测出IGH克隆性重排,2例未检测出重排。结论　在MALT淋巴瘤的诊断和淋巴组织增生性疾病的鉴别诊断中,BIOMED-2标准化体系检测IGH基因克隆性重排是一种快速可靠的方法,具有重要的临床应用价值。     

胃肠道原发B细胞性淋巴瘤的病理学特征及播散机制

目的研究胃肠道原发B细胞性淋巴瘤的病理学特征及淋巴细胞归巢受体CD44在其播散中的作用。方法对199例胃肠道原发B细胞性淋巴瘤进行病理组织学及免疫组化研究。结果胃肠道原发B细胞性淋巴瘤以DL(70.9%)发病率最高,MALT淋巴瘤(9.5%)次之。LN1染色在MALT淋巴瘤、MZC均为核周点状阳性。1例MLP肿瘤细胞LN1染色特性及形态学特征与MALT淋巴瘤相同。199例中单克隆性cIg检出率为49.7%,在MALT淋巴瘤为100%。临床Ⅲ、Ⅳ期组的CD44阳性率明显高于Ⅰ、Ⅱ期组(P<0.001);在全身弥漫播散病例CD44阳性率高于MALT内播散者。结论MALT淋巴瘤来源于MZC,其惰性生物学行为与细胞来源有关。MLP除可为多中心起源的套细胞来源外,也可是MALT淋巴瘤晚期扩散的结果。cIg检测有助于胃肠道淋巴组织良恶性疾病的鉴别诊断。CD44表达与淋巴瘤的血道播散密切相关。     

肺黏膜相关淋巴组织淋巴瘤临床特征及预后分析

  目的  分析肺黏膜相关淋巴组织（MALT）淋巴瘤的发病情况、临床病理特征、影像学表现和治疗、预后情况,探讨肺MALT淋巴瘤诊治中的相关问题。  方法  回顾性分析14例肺MALT淋巴瘤患者的临床资料、治疗反应及预后因素。  结果  14例肺MALT淋巴瘤患者发病年龄为33~73岁,平均发病年龄为（52.36±13.08）岁,高峰年龄段40~60岁,占50%。男女比例为1﹕1。其中92.86%（13/14）患者为Ⅰ~Ⅱ期病变,50.00%（7/14）患B症状,64.29%（9/14）有结外受累。2例患者行手术治疗,4例行利妥昔单抗联合化疗,3例患者行未含利妥昔单抗的化疗,1例患者行利妥昔单抗单药化疗,1例患者间断使用干扰素2年,3例患者未接受任何化疗。随访15~75个月,平均随访时间（37.86±19.52）个月,总生存率100%,总无进展生存率57.14%（8/14）。预后分析提示结外侵犯数≥2枚、Ann Arbor分期≥Ⅲ、血乳酸脱氢酶（LDH）、IgM水平升高为不良预后因素。  结论  肺MALT淋巴瘤是一种惰性淋巴瘤,进展缓慢,临床表现不典型,影像学改变缺乏特异性,诊断主要依靠病理活检。联合利妥昔单抗的免疫化疗效果好,可作为肺MALT淋巴瘤的标准治疗。      

Non-Hodgkin's Lymphoma of the Thyroid: A clinical study of twenty-two cases

Non-Hodgkin's lymphoma (NHL) of the thyroid gland is a rare disease. In the present study, the survival rate and characteristics were retrospectively analyzed in 22 patients with stage IE and IIE thyroid NHL treated with radiotherapy with or without combination chemotherapy. Seventeen NHL had histological evidence of lymphoma of mucosa-associated lymphoid tissue (MALT) type. The 5-year survival rate was 85% in all patients, with 100% and 63% respectively, for stage IE and stage IIE patients. The highly significant factor correlated with decreased determinate survival was concomitant stridor.     

29例原发腮腺非霍奇金淋巴瘤的治疗结果分析

目的探讨腮腺非霍奇金淋巴瘤的临床特点、治疗及预后.方法回顾性分析29例原发性腮腺淋巴瘤.用Kaplan-Meier法计算其生存率,用Logrank法行差异显著性检验及生存因素分析(性别、年龄、分期、是否化疗、化疗疗程、是否放射治疗、腮腺区照射剂量).结果全组5、10年总生存率分别为73.3%、51.0%,早期(ⅠE+ⅡE)病变的预后明显好于晚期(ⅢE+ⅣE)病变(χ2=15.75, P＜0.01),黏膜相关淋巴组织淋巴瘤(MALTL)好于弥漫性大B细胞淋巴瘤(DLBCL)(χ2=5.16,P＜0.05).结论腮腺淋巴瘤预后较好,以肿块切除术或浅叶切除术为主的手术仅作为明确诊断的工具;对于MALTL和早期的滤泡性淋巴瘤(FL)可单纯放射治疗,早期DLBCL需行放射治疗+化疗的综合治疗,晚期DLBCL以化疗为主.     

129例原发鼻腔非霍奇金淋巴瘤的预后分析

背景与目的：原发鼻腔非霍奇金淋巴瘤（non-Hodgkin’s lymphoma,NHL）预后较差．远处转移和局部复发率均较高．目前本病尚无标准治疗原则。本研究主要探讨影响原发鼻腔NHL的预后因素。方法：1996年1月至2002年12月共收治129例经病理证实的原发鼻腔NHL。116例经病理形态学诊断为鼻腔NK／T细胞淋巴瘤。根据Ann Arbor分期,ⅠE期102例,ⅡE期22例,ⅣE期5例。124例ⅠE／ⅡE期患者单纯放疗22例,单纯化疗7例,45例放疗后化疗,50例化疗后放疗。5例ⅣE期以化疗为主。结果：全组5年总生存率（overall survival,OS）和无病生存率（disease-freely survival,DFS）分别是68．0％和55．8％。ⅠE期和ⅡE期患者的5年OS分别是71．7％和70．6％（P=0．77）,DFS分别是60．9％和47．0％（P=0．09）。首程治疗后完全缓解（complete response,CR）的患者5年OS为83．1％,而未达CR患者的5年OS为18．0％（P〈0．01）,相应5年DFS分别为68．0％和15．5％（P〈0．01）。国际预后指数（international prognostic index,IPl）评分为0,1和≥2的5年OS分别为81．1％、60．1％和14．3％（P〈0．01）,DFS分别为68．8％、44．6％和22．5％（P〈0．01）。38例患者治疗中进展或疗后复发,远处结外器官复发占78．9％,是治疗失败主要原因。单因素分析显示,首程治疗后的CR率、一般状态评分（performance status,PS）、IPI和修订后IPI与预后相关。多因素分析显示仅治疗后的CR率是独立预后因素。结论：治疗后的CR率是影响原发鼻腔NHL的重要预后因素,原因以远处病灶治疗失败为主。     

Primary salivary gland lymphoma among Japanese: A clinicopathological study of 30 cases

To clarify the clinicopathological findings of primary salivary gland lymphoma as defined by the World Health Organization (WHO) classification, 30 Japanese patients with this disease were studied. The male to female ratio was 1:1.7 and median patient age was 57 years. The parotid gland (n = 22) was involved most frequently, followed by the submandibular gland (n = 5) and minor salivary gland (n = 3). Twenty-four (80%) cases demonstrated Stage IE, whereas only six (20%) had Stage IIE-1. None of the 30 cases had "B" symptoms or a poor performance status. The 5-year overall survival of 31 cases was 96% and 5-year failure-free survival was 77%. Histologically, 15 cases were mucosa-associated lymphoid tissue (MALT) lymphoma, seven were follicular lymphoma (FL), and six were diffuse large B-cell lymphoma (DLBCL) + MALT lymphoma and only two were DLBCL without a MALT lymphoma component. MALT lymphoma is the most frequent type of primary salivary gland lymphoma. However, FL comprised 20% of primary salivary gland lymphoma. The majority of the primary salivary gland DLBCL appear to arise from MALT type lymphoma. When appropriate therapy for histologic subtype is used, outcome of the primary salivary gland B-cell lymphoma appears excellent whether histologically indolent or aggressive.     

Primary gastric lymphoma in Jordan with special emphasis on descriptive epidemiology

The aim of this study was to examine the clinicopathological features and epidemiology of primary gastric lymphoma in Jordan as a model for Middle East countries where such data is scarce. From 1991 - 2002, 219 patients with primary gastric malignancy were managed at our hospitals. Among these there were 19 patients with primary gastric lymphoma. Pertinent data for these patients were analyzed. Primary gastric lymphoma constituted 65.5% of all gastrointestinal lymphoma and 8.7% of all gastric malignancies. Male-to-female ratio was 2.8:1. The mean age was 56 years (range 39 - 82). The incidence was 0.6/100 000. The proximal third was the most common localisation. Abdominal pain was the commonest presentation. Low-grade MALT lymphomas, high-grade MALT lymphomas, diffuse large cell B lymphomas and T cell lymphoma were found in 21.1, 26.3, 47.4 and 5.3%, respectively. Nine patients had gastrectomy followed by chemotherapy, 6 patients had palliative resection, 3 patients had chemotherapy only and the remaining patient was treated with Helicobacter pylori eradication. The mean follow-up for all patients was 42.2 months. The 5-year survival rates for stages IE (n = 5), IIE (n = 4), IIIE (n = 6) and IVE (n = 4) were 100, 67, 27 and 0%, respectively (p = 0.0003). The overall 5 years survival was 48.2%. Primary gastric lymphoma in Jordan shares some epidemiological features with western disease. Jordanian patients are detected and treated after a relatively long delay. Advanced stage at diagnosis correlated with poor outcome. There is a need of an earlier diagnosis and subsequent better care.     

胃黏膜相关淋巴样组织淋巴瘤42例临床分析

探讨胃黏膜相关淋巴样组织淋巴瘤的临床表现、病理特征和治疗方法。方法:回顾性分析1990年7月至2008年5月间42例胃MALT淋巴瘤的病理特征和临床分期等资料,并按治疗方式不同划分为单纯根除Hp组（7例）、单纯手术组（9例）、手术+根除Hp组（20例）、手术+放、化疗组（6例）,对各治疗组随访结果使用Kaplan-Meier方法进行生存率分析,Log Rank检验评估各组间的统计学差异。结果:全组患者均接受胃镜检查,确诊率26.2%（11/42）,HP染色阳性率70.6%（24/34）。免疫表型分析证实全部为B细胞性淋巴瘤。全组Cotswolds改良Ann Arbor分期:ⅠE2期17例,ⅡE1期16例,ⅡE2期6例,ⅢE期2例,Ⅳ期1例。各组5年生存率分别为100%、83.7%、82.4%及43.0%（P=0.027）。结论:胃MALT淋巴瘤的临床表现和辅助检查均无明显特异性,故初治时接受手术治疗的患者较多。病理确诊者可首选根除Hp治疗,疗效与手术无异;晚期患者可在术后选择放、化疗等综合治疗,但远期生存率相对较差。      

Breast lymphoma: favorable prognosis after treatment with standard combination chemotherapy

PURPOSE: This paper is to determine the clinicopathological features and outcome of patients with breast lymphoma seen at a single institution. PATIENTS AND METHODS: We have reviewed data on 14 patients with breast lymphoma seen at our institution from 1990 to 2003. RESULTS: All patients were female, with a median age of 47.6 years. Diffuse large B-cell lymphoma (DLBCL) was observed in 9 cases, while follicular, Burkitt's, small lymphocytic, MALT and T-cell lymphoma were observed in 1 case each. 5 patients (35.7%) had stage IE disease, 6 patients (42.9%) had stage IIE disease and 3 patients (21.4%) had stage IV disease. Standard CHOP with or without rituximab was given to all patients with aggressive breast lymphoma (n = 10), while 1 patient with Burkitt's lymphoma received a CHOP-based regimen. The 3-year actuarial survival estimate among all 11 patients with aggressive breast lymphoma was 73%. Among those with localized disease, the estimated 3-year survival was 90%. The actuarial 3-year overall survival (OS) estimate for the entire cohort of 14 patients was 76.9%. CONCLUSION: Our results indicate that breast lymphoma is not associated with an inferior outcome when treated with standard CHOP-based chemotherapy.     

Localised extranodal non-Hodgkin's lymphoma of the gastrointestinal tract: Sheffield Lymphoma Group experience (1989-1998)

Extranodal non-Hodgkin's lymphoma (NHL) of the gastrointestinal tract accounts for about one third of all extranodal NHL. We retrospectively reviewed the clinical and histopathologic records of 71 patients with stage IE and IIE primary gastrointestinal NHL referred to the Sheffield Lymphoma Group (SLG) from 1989 to 1998. Cross-referencing with the Hospital Histopathology Department database revealed that only two-thirds of all cases were seen by the Group. The most common primary site was the stomach (45 patients, 63% of all cases), followed by the small intestine (16, 23%) and large intestine (9, 13%). The median age of patients was 62 years; the majority of patients presented with stage I (61%) and/or grade (65%) NHL. Mucosa-associated lymphoid tissue (MALT) lymphomas were the largest histologic subtype seen (57%), with 87% of these arising from the stomach; next most frequent was the diffuse large B-cell subtype (21% of all cases) most frequently arising from the intestine (60%). For treatment of gastric MALT lymphoma, a combined approach (surgery followed by chemotherapy, antihelicobacter therapy followed by chemotherapy) was favoured (22 cases). Five-year and 10-year overall survivals were 52% and 45% respectively. Knowledge of the Revised European American Lymphoma classification and the Helicobacter pylori/MALT association has influenced treatment approaches over the 10-year study period. For small intestinal lymphoma, surgery (with or without chemotherapy) gave 5- and 10-year survivals of 60%. Overall survival of patients with primary gastrointestinal lymphoma managed by the SLG is similar to that reported from other large series.     

Primary malignant lymphoma of the thyroid: a clinicopathological analysis.

A retrospective analysis of 70 patients with primary malignant lymphoma of the thyroid treated at this institute between 1965-1983 has been conducted. The clinicopathological features and prognostic factors have been studied. The mean age was 67.5 years and there was a marked female:male ratio of 8:1. A total of 32 (45.7%) Stage IE and 38 (54.3%) Stage IIE patients were identified. In 64 cases histological material was reviewed and classified employing the Kiel classification. All the tumors were of B cell lineage and the majority were follicle center cell type. A biopsy only was performed in 27 patients, lobectomy in 11 patients, subtotal thyroidectomy in 27 and macroscopic thyroidectomy in 5 patients. All patients were treated with radiotherapy. The overall 5-year survival was 42%, with 63% for Stage IE and 27% for Stage IIE. The corrected overall 5-year survival was 49% with 68% for Stage IE and 36% for Stage IIE. The corresponding overall relapse free survival was 42% with 60% for Stage IE, and 31% for Stage IIE. Factors of prognostic significance for relapse and survival were stage, radiotherapy dose, stridor, retrosternal extension and fixation.     

Primary thyroid lymphoma: the 40 year experience of a UK lymphoma treatment centre

We report the 40-year unselected experience of a UK lymphoma treatment centre. Between 1970 and 2010, 3363 cases of non-Hodgkin lymphoma were managed by the Sheffield Lymphoma Team. Seventy cases of primary thyroid lymphoma were identified during this time. This retrospective review of the clinical and pathological features of patients with thyroid lymphoma comprises one of the largest series conducted in the UK. The series included 57 females and 13 males with a median age at diagnosis of 69.5. The pathological subtypes were diffuse large B-cell lymphoma (DLBCL) in 50 patients, MALT lymphoma in 13, indolent B-cell lymphoma not otherwise specified (NOS) in 6 and T cell lymphoma in one patient. Of the 64 patients fully staged, 53 had Stage IE and 11 Stage IIE disease. Management modalities included surgery, chemotherapy, radiotherapy or combination treatment. Five- year survival rates for DLBCL, MALT lymphoma and indolent B-cell lymphoma NOS were 45%, 62% and 75%, respectively, with a median overall survival of all histological subtypes of 68 months (range 0-148) or 5.7 years. The outcomes of this series confirm previous experience. If treatment is needed after surgery radiotherapy alone is sufficient for Stage I and II low grade thyroid lymphoma. Combination chemotherapy or adequate chemotherapy followed by radiotherapy is warranted in high grade thyroid lymphoma.